Drugs / MASCT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02844881 | Jul 2016 → Jul 2018 | T-cell non-Hodgkin lymphoma, cancer | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MASCT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02844881 ↗ |
| Modality | Cell therapy | “Multiple antigens specific cellular therapy (MASCT) is a new immunotherapy” NCT02844881 ↗ |
| Route | Intravenous | “cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28” NCT02844881 ↗ |